Skip to content

Analysis of the role and mechanism of PMBC and gut microflora in heart failure based on transcriptome

Analysis of the role and mechanism of PMBC and gut microflora in heart failure based on transcriptome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049635
Enrollment
Unknown
Registered
2021-08-07
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Case series:N/A

Sponsors

The First People's Hospital of Changzhou (The Third Affiliated Hospital of Soochow University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1.HFrEF group: (1) Aged >= 18 years, gender is not limited; (2) The patient has certain language expression and comprehension ability, understands and voluntarily fills in the informed consent form, and cooperates with the completion of blood test, stool collection and scale filling; (3) Patients diagnosed with HFrEF according to the 2019 ESC-HFA diagnostic criteria. 2.HFpEF group: (1) Aged >= 18 years, gender is not limited; (2) The patient has certain language expression and comprehension ability, understands and voluntarily fills in the informed consent form, and cooperates with the completion of blood test, stool collection and scale filling; (3) Patients diagnosed with HFpEF according to the 2019 ESC-HFA diagnostic criteria.

Exclusion criteria

Exclusion criteria: 1. Patients with severe respiratory, digestive, endocrine and blood system diseases; 2. Patients with severe liver and kidney damage; 3. Those with pacemaker implantation before enrollment; 4. Those suffering from any infectious diseases (including bacterial and viral infections); 5. Pregnant and lactating patients; 6. Cancer and mental patients; 7. Those who cannot cooperate for other reasons, have poor compliance, and are inconvenient to follow up; 8. History of drug abuse; 9. Participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Gene expression level;

Secondary

MeasureTime frame
The general condition of the patient;Laboratory examination and auxiliary examination;Vital signs (temperature, respiration, heart rate, blood pressure);

Countries

China

Contacts

Public ContactYang Ling

The First People's Hospital of Changzhou (The Third Affiliated Hospital of Soochow University)

linda_yl@sina.com+86 13616110633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026